Long-term follow-up from the SOFT study shows adding ovarian function suppression (OFS) for premenopausal women under 35 with HR-positive breast cancer yields an 18% absolute improvement in breast cancer-free interval. The speaker notes these gains are unprecedented since the introduction of trastuzumab, highlighting OFS as a critical, high-impact intervention for this specific patient group.

A prospective registry trial demonstrated the real-world clinical utility of the BCI test. Its results directly changed physicians' recommendations for or against extended endocrine therapy in 41% of cases, while also increasing patient confidence in the shared treatment decision.

A retrospective analysis of the MA27 trial suggests patients with invasive lobular cancer have worse outcomes with exemestane. This is attributed to an androgenic metabolite, prompting experts to prefer anastrozole or letrozole for this specific histological subtype.

Data from the Optima trial shows the ProSigna (PAM50) gene signature can identify premenopausal ER+ breast cancer patients, even those with high nodal burden, who can safely forgo chemotherapy. For those with a low-risk score, adequate ovarian suppression alone provides sufficient benefit, marking a major step in treatment de-escalation.

Even within recent major clinical trials like HER2CLIMB-05, less than half of eligible hormone receptor-positive patients received endocrine therapy. This highlights a critical and widespread gap in clinical practice, as this treatment adds significant benefit.

Counterintuitively, the SOFT trial showed pre-menopausal women with BCI-low tumors (less driven by estrogen receptors) derived more benefit from an aromatase inhibitor (AI) plus ovarian suppression compared to tamoxifen. This suggests the most aggressive endocrine therapy is crucial for biologically aggressive, less ER-sensitive cancers.

The SET assay, measuring estrogen receptor activity, re-analyzed the NSABP B42 trial and found a 'very high SET' subgroup. This group experienced a massive 17% absolute improvement in 10-year breast cancer-free interval with extended letrozole, unmasking a profound benefit that was diluted in the overall trial results.

A registry trial of 3,000 women showed that BCI results caused physicians to change their initial recommendations for or against extended endocrine therapy in 41% of cases. The genomic test also significantly increased patient confidence in their treatment decisions, demonstrating its real-world utility in shared decision-making.

Counterintuitively, in premenopausal women on ovarian suppression, the more potent endocrine therapy (Aromatase Inhibitor) provided the most benefit over Tamoxifen in BCI-Low tumors. These tumors are less ER-driven, suggesting other pathways make them vulnerable to maximal estrogen deprivation.